keyword
MENU ▼
Read by QxMD icon Read
search

Lispro

keyword
https://www.readbyqxmd.com/read/28029018/exenatide-versus-insulin-lispro-added-to-basal-insulin-in-a-subgroup-of-korean-patients-with-type-2-diabetes-mellitus
#1
Kun Ho Yoon, Elise Hardy, Jenny Han
BACKGROUND: The prevalence of type 2 diabetes mellitus (T2DM) and obesity is increasing in Korea. Clinical studies in patients with T2DM have shown that combining the glucagon-like peptide-1 receptor agonist exenatide twice daily with basal insulin is an effective glucose-lowering strategy. However, these studies were predominantly conducted in non-Asian populations. METHODS: We conducted a subgroup analysis of data from a multinational, 30-week, randomized, open-label trial to compare the effects of exenatide twice daily (n=10) or three times daily mealtime insulin lispro (n=13) among Korean patients with T2DM inadequately controlled (glycosylated hemoglobin [HbA1c] >7...
December 26, 2016: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/27988180/factors-associated-with-reaching-or-not-reaching-target-hba1c-after-initiation-of-basal-or-premixed-insulin-in-patients-with-type-2-diabetes
#2
A J Scheen, H Schmitt, H H Jiang, T Ivanyi
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1c) levels by analysing the respective contributions of fasting hyperglycaemia (FHG), also referred to as basal hyperglycaemia, vs postprandial hyperglycaemia (PHG) before and after initiation of a basal or premixed insulin regimen in patients with type 2 diabetes. METHODS: This post-hoc analysis of insulin-naïve patients in the DURABLE study randomised to receive either insulin glargine or insulin lispro mix 25 evaluated the percentages of patients achieving a target HbA1c of <7...
December 14, 2016: Diabetes & Metabolism
https://www.readbyqxmd.com/read/27987252/similar-pharmacokinetics-and-pharmacodynamics-of-rapid-acting-insulin-lispro-products-sar342434-and-us-and-eu-approved-humalog%C3%A2-in-subjects-with-type-1-diabetes
#3
C Kapitza, I Nowotny, A Lehmann, K Bergmann, B Rotthaeuser, L Nosek, R Becker
AIMS: To compare the pharmacokinetics (PK) and pharmacodynamics (PD) of three rapid-acting insulin lispro products: SAR342434 solution, United States (US)-approved Humalog® and European Union (EU)-approved Humalog®. METHODS: In a single-centre, randomized, double-blind, three-treatment, three-period, six-sequence, crossover, euglycaemic clamp study (NCT02273258), adult male subjects with type 1 diabetes were randomized to receive 0.3 U/kg of SAR342434 solution, US-approved and EU-approved Humalog® under fasted conditions...
December 17, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27964837/efficacy-of-sitagliptin-for-the-hospital-management-of-general-medicine-and-surgery-patients-with-type-2-diabetes-sita-hospital-a-multicentre-prospective-open-label-non-inferiority-randomised-trial
#4
Francisco J Pasquel, Roma Gianchandani, Daniel J Rubin, Kathleen M Dungan, Isabel Anzola, Patricia C Gomez, Limin Peng, Israel Hodish, Tim Bodnar, David Wesorick, Vijay Balakrishnan, Kwame Osei, Guillermo E Umpierrez
BACKGROUND: The role of incretin-based drugs in the treatment of patients with type 2 diabetes admitted to hospital has not been extensively assessed. In this study, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basal insulin with a basal-bolus insulin regimen for the management of patients with type 2 diabetes in general medicine and surgery in hospitals. METHODS: We did a multicentre, prospective, open-label, non-inferiority randomised clinical trial (Sita-Hospital) in five hospitals in the USA, enrolling patients aged 18-80 years with type 2 diabetes and a random blood glucose concentration of 7·8-22·2 mmol/L who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of 0·6 units per kg or less, admitted to general medicine and surgery services...
December 7, 2016: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/27905149/scope-limitations-of-fmoc-chemistry-spps-based-approaches-to-the-total-synthesis-of-insulin-lispro-via-ester-insulin
#5
Stephen Kent, Balamurugan Dhayalan, Kalyaneswar Mandal, Nischay Rege, Michael Weiss, Simon Eitel, Thomas Meier, Ralph Schoenleber
We have systematically explored three approaches based on Fmoc chemistry SPPS for the total chemical synthesis of the key depsipeptide intermediate for the efficient total chemical synthesis of insulin. The approaches used were: stepwise Fmoc chemistry SPPS; the 'hybrid method', in which maximally-protected peptide segments made by Fmoc chemistry SPPS are condensed in solution; and, native chemical ligation using peptide-thioester segments generated by Fmoc chemistry SPPS. A key building block in all three approaches was a Glu[Oβ(Thr)] ester-linked dipeptide equipped with a set of orthogonal protecting groups compatible with Fmoc chemistry SPPS...
November 30, 2016: Chemistry: a European Journal
https://www.readbyqxmd.com/read/27860499/premixed-insulin-analogue-compared-with-basal-plus-regimen-for-inpatient-glycemic-control
#6
Abraham Edgar Gracia-Ramos, María Del Pilar Cruz-Domínguez, Eduardo Osiris Madrigal-Santillán, José Antonio Morales-González, Eduardo Madrigal-Bujaidar, José Leopoldo Aguilar-Faisal
BACKGROUND: No previous studies have investigated the use of a premixed insulin analogue in a hospital setting. OBJECTIVE: To compare the efficacy and safety of treatment with premixed insulin analogue (insulin lispro mix 75/25, LM75/25) with the basal-plus regimen with insulin glargine in hospitalized patients with type 2 diabetes (T2D). MATERIALS AND METHODS: A randomized clinical trial in hospitalized patients with T2D and glucose >140 mg/dL on admission was performed...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27776251/the-effects-of-exenatide-twice-daily-compared-to-insulin-lispro-added-to-basal-insulin-in-latin-american-patients-with-type-2-diabetes-a-retrospective-analysis-of-the-4b-trial
#7
Silvia Beatriz Gorban de Lapertosa, Gustavo Frechtel, Elise Hardy, Leobardo Sauque-Reyna
AIMS: Socioeconomic changes in Latin American countries have led to an increased prevalence of type 2 diabetes (T2D). We examined the effects of exenatide twice daily (BID) or insulin lispro, each added to insulin glargine, in Latin American patients with T2D. METHODS: This was a subgroup analysis of patients from Argentina and Mexico in the 4B study (N=114). Patients with glycated hemoglobin (HbA1c) of 7.0-10.0% (53-86mmol/mol) after 12weeks of intensive basal insulin optimization were randomized to exenatide BID or thrice-daily insulin lispro added to insulin glargine and metformin...
December 2016: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/27660663/insulin-lispro-low-mixture-twice-daily-vs-basal-insulin-glargine-once-daily-and-prandial-insulin-lispro-once-daily-as-insulin-intensification-strategies-in-patients-with-type-2-diabetes-latin-american-subpopulation-analysis-of-a-randomized-trial
#8
Arturo Rojas, Georgina Sposetti, Jorge L Gross, Douglas Eugenio Barbieri, Ran Duan, Bruno Linetzky, Janaina Martins De Lana, Oded Stempa, Angel Rodriguez
BACKGROUND: This post hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation with type 2 diabetes mellitus (T2DM). METHODS: A phase 4, randomized, open-label, parallel-arm trial included participants aged 18-75 years with T2DM taking once-daily insulin glargine and stable doses of metformin and/or pioglitazone with glycated hemoglobin (HbA1c) 7...
2016: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/27563254/comparison-of-efficacy-and-safety-of-two-starting-insulin-regimens-in-non-asian-asian-indian-and-east-asian-patients-with-type-2-diabetes-a-post-hoc-analysis-of-the-paradigm-study
#9
Linong Ji, Kyung Wan Min, Juliana Oliveira, Thomas Lew, Ran Duan
OBJECTIVE: The objective of this study was to explore the efficacy and safety of insulin lispro mix 25 (25% insulin lispro and 75% insulin lispro protamine suspension [LM25]) or insulin glargine plus insulin lispro (G+L) in insulin-naïve patients with type 2 diabetes from different racial/ethnic groups. METHODS: Three subgroups from the PARADIGM study were analyzed post hoc: non-Asian (n=130), Asian Indian (n=106), and East Asian (n=89). RESULTS: All subgroups recorded glycated hemoglobin (HbA1c) reductions: non-Asian (LM25, -2...
2016: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/27553192/an-assessment-of-the-central-disposition-of-intranasally-administered-insulin-lispro-in-the-cerebrospinal-fluid-of-healthy-volunteers-and-beagle-dogs
#10
Stephen Lowe, Emanuele Sher, Graham Wishart, Kimberley Jackson, Eunice Yuen, Claire Brittain, Siew Chinn Fong, David O Clarke, William H Landschulz
Intranasally administered regular insulin and insulin aspart have shown cognitive benefit for patients with Alzheimer's disease (AD). To support development of intranasally administered insulin analogs for AD, the central disposition of intranasal insulin lispro in the cerebrospinal fluid (CSF) of healthy volunteers was investigated. Healthy volunteers (N = 8) received two sequential doses of intranasal insulin lispro (48 or 80 IU followed by 160 IU) by Aero Pump in an open-label, single-period study with serial CSF and serum sampling over 5 hours after each dose...
August 23, 2016: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/27540462/treatment-with-insulin-analogs-especially-glargine-and-lispro-associates-with-better-renal-function-and-higher-hemoglobin-levels-in-type-1-diabetic-patients-with-impaired-kidney-function
#11
Christoph Hasslacher, Felix Kulozik, Justo Lorenzo Bermejo
OBJECTIVES: The influence of type of insulin treatment - insulin analogs versus human insulin - on the development of diabetes related vascular complications has been sparsely investigated. We examine here possible differences regarding kidney function and hemoglobin levels. METHODS: Multiple linear regression was used to investigate the relationship between the following characteristics measured in 509 type 1 diabetic patients who were recruited in an outpatient practice: current clinical status and treatment modalities, type of injected insulin and the routine laboratory parameters hemoglobin, HbA1c, serum creatinine, eGFR, hs CRP and urinary albumin/creatinine ratio...
August 2016: Therapeutic Advances in Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27528391/addition-of-20-kda-peg-to-insulin-lispro-alters-absorption-and-decreases-clearance-in-animals
#12
Mary Pat Knadler, Tri-Hung Nguyen, Kristina Campanale, Michael J De Veer, John M Beals, Shun Li, Ryan Hansen, Angela Siesky, M Dodson Michael, Christopher J H Porter
PURPOSE: Determine the pharmacokinetics of insulin peglispro (BIL) in 5/6-nephrectomized rats and study the absorption in lymph duct cannulated (LDC) sheep. METHODS: BIL is insulin lispro modified with 20-kDa linear PEG at lysine B28 increasing the hydrodynamic size to 4-fold larger than insulin lispro. Pharmacokinetics of BIL and insulin lispro after IV administration were compared in 5/6-nephrectomized and sham rats. BIL was administered IV or SC into the interdigital space of the hind leg, and peripheral lymph and/or serum samples were collected from both LDC and non-LDC sheep to determine pharmacokinetics and absorption route of BIL...
December 2016: Pharmaceutical Research
https://www.readbyqxmd.com/read/27517679/clinical-effects-and-safety-of-direct-acting-insulin-analogs-in-patients-with-type-1-diabetes-a-nation-wide-observational-cohort-study
#13
Vincent Lak, Ann-Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Eliasson
INTRODUCTION: Studies comparing direct-acting insulin analogs (DAIs) in terms of effectiveness and long-term safety are scarce. Our aim was to explore these variables in clinical practice among patients with type 1 diabetes, including the elderly and those with renal impairment. METHODS: We linked four national registers in a population-based cohort study. Patients with type 1 diabetes and continuous use of all currently available DAIs (lispro, aspart, or glulisine) in 2005-2013 were monitored for up to 7...
September 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27411698/insulin-injection-into-lipohypertrophic-tissue-blunted-and-more-variable-insulin-absorption-and-action-and-impaired-postprandial-glucose-control
#14
Susanne Famulla, Ulrike Hövelmann, Annelie Fischer, Hans-Veit Coester, Lidia Hermanski, Matthias Kaltheuner, Lars Kaltheuner, Lutz Heinemann, Tim Heise, Laurence Hirsch
OBJECTIVE: Lipohypertrophy (LHT) is common in insulin-treated patients but its exact impact on insulin absorption and action is unclear. RESEARCH DESIGN AND METHODS: In this crossover study, 13 patients with type 1 diabetes received subcutaneous abdominal injections of 0.15 units/kg insulin lispro into LHT (confirmed by examination and ultrasound) and normal adipose tissue (NAT). On one day, a euglycemic clamp was performed with two injections each into LHT and NAT, and on another day one injection per region was given before a standardized mixed meal (75 g carbohydrates), all in randomized order...
September 2016: Diabetes Care
https://www.readbyqxmd.com/read/27393697/a-randomized-clinical-trial-comparing-basal-insulin-peglispro-and-insulin-glargine-in-combination-with-prandial-insulin-lispro-in-patients-with-type-1-diabetes-imagine-1
#15
(no author information available yet)
This article will be part of a supplement and will be republished when the entire issue is complete.
July 8, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27390032/20-years-of-insulin-lispro-in-pediatric-type-1-diabetes-a-review-of-available-evidence
#16
Kevin Kaiserman, Heike Jung, Imane Benabbad, Beate Karges, Michel Polak, Myriam Rosilio
BACKGROUND: Insulin lispro, the first rapid-acting insulin analog, was developed 20 years ago and has been studied in multiple situations and various populations. OBJECTIVE: To review the literature on the use of insulin lispro in children, adolescents, and young adults. PATIENTS: Children, adolescents, and young adults with type-1-diabetes. METHODS: One hundred and twenty-two relevant publications, identified by a systematic (MEDLINE) and manual literature search, were reviewed...
July 8, 2016: Pediatric Diabetes
https://www.readbyqxmd.com/read/27371341/comparison-of-insulin-lispro-mix-25-with-insulin-lispro-mix-50-as-insulin-starter-in-chinese-patients-with-type-2-diabetes-mellitus-classify-study-a-subgroup-analysis-of-a-phase-4-open-label-randomized-trial
#17
Qing Su, Chao Liu, Hongting Zheng, Jun Zhu, Peng Fei Li, Lei Qian, Wen Ying Yang
BACKGROUND: Premixed insulins are recommended starter insulins in Chinese patients after oral antihyperglycemic medication (OAM) failure. Here, we compared the efficacy and safety of Insulin Lispro Mix25 (LM25) twice daily (BID) and Insulin Lispro Mix50 (LM50) BID as starter insulin regimen in Chinese patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control with OAMs. METHODS: Primary efficacy outcome in this open-label, parallel, randomized clinical trial was change in hemoglobin A1c (HbA1c) from baseline to 26 weeks...
July 1, 2016: Journal of Diabetes
https://www.readbyqxmd.com/read/27356188/the-cost-effectiveness-of-exenatide-twice-daily-bid-versus-insulin-lispro-three-times-daily-tid-as-add-on-therapy-to-titrated-insulin-glargine-in-patients-with-type-2-diabetes
#18
J Gordon, P McEwan, U Sabale, B Kartman, B H R Wolffenbuttel
OBJECTIVE: To evaluate the cost-effectiveness of exenatide twice daily (BID) versus bolus insulin lispro three times daily (TID) as add-on therapy when glycemic control is suboptimal with titrated basal insulin glargine and metformin. METHODS: The analysis was based on the recent 4B Study, which compared exenatide BID and lispro TID as add-on therapies in subjects with type 2 diabetes insufficiently controlled despite titrated insulin glargine. The Cardiff Diabetes Model was used to simulate patient costs and health benefits beyond the 4B Study...
June 29, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27333446/improving-efficacy-of-inhaled-technosphere-insulin-afrezza-by-postmeal-dosing-in-silico-clinical-trial-with-the-university-of-virginia-padova-type-1-diabetes-simulator
#19
Roberto Visentin, Clemens Giegerich, Robert Jäger, Raphael Dahmen, Anders Boss, Marshall Grant, Chiara Dalla Man, Claudio Cobelli, Thomas Klabunde
BACKGROUND: Technosphere(®) insulin (TI), an inhaled human insulin with a fast onset of action, provides a novel option for the control of prandial glucose. We used the University of Virginia (UVA)/Padova simulator to explore in-silico the potential benefit of different dosing regimens on postprandial glucose (PPG) control to support the design of further clinical trials. Tested dosing regimens included at-meal or postmeal dosing, or dosing before and after a meal (split dosing). METHODS: Various dosing regimens of TI were compared among one another and to insulin lispro in 100 virtual type-1 patients...
September 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27279266/continuous-glucose-monitoring-in-patients-with-type-2-diabetes-treated-with-glucagon-like-peptide-1-receptor-agonist-dulaglutide-in-combination-with-prandial-insulin-lispro-an-award-4-substudy
#20
Johan Jendle, Marcia A Testa, Sherry Martin, Honghua Jiang, Zvonko Milicevic
AIM: To conduct a substudy, using 24-hour continuous glucose monitoring (CGM), of the AWARD-4 trial, which was designed to compare insulin + glucagon-like peptide-1 receptor agonist treatment with an insulin-only regimen. METHODS: The AWARD-4 trial randomized 884 conventional insulin regimen-treated patients to dulaglutide 1.5 mg, dulaglutide 0.75 mg and glargine, all in combination with prandial insulin lispro. The CGM substudy included 144 patients inserted with a Medtronic CGMS iPro CGM device to enable 3-day glucose monitoring...
October 2016: Diabetes, Obesity & Metabolism
keyword
keyword
42766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"